The keynote presentation by Dr. Skoulidis focused on the management of KRAS mutant non-small cell lung cancer, particularly non-G12C mutations. KRAS G12C mutations are prevalent in 40% of cases, leaving 60% for other mutations. The development of covalent G12C inhibitors like zoldonrasib and adagrasib has been a breakthrough. He discussed various inhibitors targeting different KRAS mutations, including pan-RAS inhibitors like diraxon rasib, which showed a 38% objective response rate in clinical trials. He also highlighted the importance of understanding drug-tolerant persister cells and the potential for feedback activation of the pathway through wild-type KRAS, HRAS, and NRAS.